Annals of medicine and surgery (2012) · 2020
Corneal parameters 18 Months following collagen cross-linkage treatment (CXL) for keratoconus in western Saudi Arabia: A prospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bamahfouz Ashjan, Jouhargy Serene, Basheikh Ahmed, Alqahtani Nawaf, Elhams Yaser, Aldosari Ayat, Khattab Faisal, Alkhoutani Ensa, Alfaqih Khadija
Аннотация
INTRODUCTION: keratoconus is a common disease in the general population, with prevalence ranging up to 200 per 100 000 with a reported increase in Saudi Arabia. Collagen Cross-Linkage is now an established treatment in isolation and in conjunction with other modalities for managing keratoconus. Our aim is to evaluate using a cohort study the impact of the treatment over a course of 18 months.
METHODS: To evaluate the impact of 18 months after collagen cross-linkage treatment and its determinants in eyes with keratoconus in Western Saudi Arabia. A one-armed prospective cohort study design on 45 patients with Stage I, II, III and IV keratoconus who were treated by Collagen Cross-Linkage modality was developed at our institute between 2018 and 2019 to establish the success rate of corneal ectasia stabilization of the disease.
RESULTS: Demographic data and grades of keratoconus (Amsler - Krumiech classification) at presentation were correlated to changes in corneal parameters 18 months after CXL compared to that at presentation. Stage I, II, III and IV keratoconus were 13, 14, 2 and 16 eyes respectively. The study showed that the K max significantly declined (P = 0.05) while spherical equivalent refractive status changed from median -1.5D to -2.27D (P = 0.002). Meanwhile, Central corneal thickness significantly reduced (P = 0.001).
CONCLUSION: CXL can prove to be efficient in the treatment of Keratoconus and more studies should study ways to improve and implement this treatment plan to such patients.
METHODS: To evaluate the impact of 18 months after collagen cross-linkage treatment and its determinants in eyes with keratoconus in Western Saudi Arabia. A one-armed prospective cohort study design on 45 patients with Stage I, II, III and IV keratoconus who were treated by Collagen Cross-Linkage modality was developed at our institute between 2018 and 2019 to establish the success rate of corneal ectasia stabilization of the disease.
RESULTS: Demographic data and grades of keratoconus (Amsler - Krumiech classification) at presentation were correlated to changes in corneal parameters 18 months after CXL compared to that at presentation. Stage I, II, III and IV keratoconus were 13, 14, 2 and 16 eyes respectively. The study showed that the K max significantly declined (P = 0.05) while spherical equivalent refractive status changed from median -1.5D to -2.27D (P = 0.002). Meanwhile, Central corneal thickness significantly reduced (P = 0.001).
CONCLUSION: CXL can prove to be efficient in the treatment of Keratoconus and more studies should study ways to improve and implement this treatment plan to such patients.